Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
| Autor: | Haresh Patel, Jonathan P. Eskander, Robert Sherburne, Amnon A Berger, Ivan Urits |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hypertriglyceridemia Population Infectious Disease Disease 030204 cardiovascular system & hematology law.invention 03 medical and health sciences 0302 clinical medicine law Anesthesiology Pandemic medicine Internal Medicine Intensive care medicine education education.field_of_study business.industry Mortality rate Hypertriglyceridemia General Engineering cytokine release syndrome (crs) medicine.disease Intensive care unit ards (acute respiratory distress syndrome) covid-19 inflammation omega-3 business 030217 neurology & neurosurgery |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly patients, as well as those requiring intensive care unit (ICU) care. The role of inflammation in symptomatic COVID-19 is being studied, and it is hypothesized that hyper-inflammation is a causative factor in severe COVID-19 disease. Treatment options are limited and mostly rely on supportive care. Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy. Though it has been shown to act as an anti-inflammatory, it is not currently indicated for that purpose. Here, we describe, for the first time, the successful treatment of a COVID-19 patient with IPE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|